198 related articles for article (PubMed ID: 36047966)
1. Pancreatic ductal adenocarcinoma cells regulated the gemcitabine-resistance function of CAFs by LINC00460.
Zhu XX; Li JH; Ni X; Wu X; Hou X; Li YX; Li SJ; Zhao W; Yin XY
Cancer Sci; 2022 Nov; 113(11):3735-3750. PubMed ID: 36047966
[TBL] [Abstract][Full Text] [Related]
2. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
Zhang L; Yao J; Li W; Zhang C
Oncol Res; 2018 Jul; 26(6):827-835. PubMed ID: 28477403
[TBL] [Abstract][Full Text] [Related]
3. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
[TBL] [Abstract][Full Text] [Related]
4. SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer.
Zhang X; Zhao P; Wang C; Xin B
Biochem Biophys Res Commun; 2019 Mar; 510(4):508-514. PubMed ID: 30737032
[TBL] [Abstract][Full Text] [Related]
5. LncRNA AB209630 inhibits gemcitabine resistance cell proliferation by regulating PI3K/AKT signaling in pancreatic ductal adenocarcinoma.
Wang L; Wang F; Na L; Yu J; Huang L; Meng ZQ; Chen Z; Chen H; Ming LL; Hua YQ
Cancer Biomark; 2018; 22(1):169-174. PubMed ID: 29526843
[TBL] [Abstract][Full Text] [Related]
6. Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma.
Fu D; Yan J; Zhang Z; Liu Y; Ma X; Ding J; Yang S; Zhao R; Chang A; Gao C; Liu J; Zhao T; Wang X; Huang C; Gao S; Ma Y; Tang B; Feng Y; Wang H; Hao J
Cancer Biol Med; 2023 Jun; 20(8):599-626. PubMed ID: 37381714
[TBL] [Abstract][Full Text] [Related]
7. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
Ma L; Fan Z; Du G; Wang H
Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
[TBL] [Abstract][Full Text] [Related]
8. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
9. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.
Calabretta S; Bielli P; Passacantilli I; Pilozzi E; Fendrich V; Capurso G; Fave GD; Sette C
Oncogene; 2016 Apr; 35(16):2031-9. PubMed ID: 26234680
[TBL] [Abstract][Full Text] [Related]
10. LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma.
Yang F; Li X; Zhang L; Cheng L; Li X
J Pharmacol Sci; 2018 Jun; 137(2):116-121. PubMed ID: 29960845
[TBL] [Abstract][Full Text] [Related]
11. RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma.
Tu Q; Liu X; Yao X; Li R; Liu G; Jiang H; Li K; Chen Q; Huang X; Chang Q; Xu G; Zhu H; Shi P; Zhao B
J Exp Clin Cancer Res; 2022 Sep; 41(1):274. PubMed ID: 36109793
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
[TBL] [Abstract][Full Text] [Related]
13. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
She C; Wu C; Guo W; Xie Y; Li S; Liu W; Xu C; Li H; Cao P; Yang Y; Wang X; Chang A; Feng Y; Hao J
J Exp Clin Cancer Res; 2023 Sep; 42(1):238. PubMed ID: 37697370
[TBL] [Abstract][Full Text] [Related]
14. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
[TBL] [Abstract][Full Text] [Related]
15. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
[TBL] [Abstract][Full Text] [Related]
16. Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma.
Wang Z; Chen Y; Lin Y; Wang X; Cui X; Zhang Z; Xian G; Qin C
Int J Oncol; 2017 Oct; 51(4):1239-1248. PubMed ID: 28849150
[TBL] [Abstract][Full Text] [Related]
17. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs.
Qi R; Bai Y; Li K; Liu N; Xu Y; Dal E; Wang Y; Lin R; Wang H; Liu Z; Li X; Wang X; Shi B
Drug Resist Updat; 2023 May; 68():100960. PubMed ID: 37003125
[TBL] [Abstract][Full Text] [Related]
18. CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy.
Liu ZD; Shi YH; Xu QC; Zhao GY; Zhu YQ; Li FX; Ma MJ; Ye JY; Huang XT; Wang XY; Xu X; Wang JQ; Zhao W; Yin XY
Cancer Lett; 2024 Mar; 585():216640. PubMed ID: 38290659
[TBL] [Abstract][Full Text] [Related]
19. Tumor-derived interleukin 35 mediates the dissemination of gemcitabine resistance in pancreatic adenocarcinoma.
Sun H; Ge Y; Liu J; Li Z; Li H; Zhao T; Wang X; Feng Y; Wang H; Gao S; Shi L; Yang S; Sun P; Chang A; Hao J; Huang C
Oncogene; 2024 Mar; 43(11):776-788. PubMed ID: 38243080
[TBL] [Abstract][Full Text] [Related]
20. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
